Filing Details
- Accession Number:
- 0001214659-21-000756
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-25 16:31:45
- Reporting Period:
- 2021-01-21
- Accepted Time:
- 2021-01-25 16:31:45
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1576263 | Mirati Therapeutics Inc. | MRTX | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1370348 | A Craig Johnson | C/O Mirati Therapeutics Inc. 9393 Towne Centre Drive, Ste 200 San Diego CA 92121 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-01-21 | 15,000 | $20.54 | 18,475 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-01-21 | 3,505 | $210.01 | 14,970 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-21 | 3,183 | $210.81 | 11,787 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-21 | 4,562 | $211.94 | 7,225 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-21 | 3,372 | $212.97 | 3,853 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-21 | 44 | $213.62 | 3,809 | No | 4 | S | Direct | |
Common Stock | Disposition | 2021-01-21 | 334 | $214.75 | 3,475 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non Qualified Stock Option (right to buy) | Disposition | 2021-01-21 | 15,000 | $0.00 | 15,000 | $20.54 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2024-09-08 | No | 4 | M | Direct |
Footnotes
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2020.
- This transaction was executed in multiple trades at prices ranging from $209.37 to $210.355. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $210.39 to $211.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $211.40 to $212.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $212.52 to $213.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $214.62 to $215.065. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant.